Press release
Relapsing refractory multiple myeloma Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
Relapsing Refractory Multiple Myeloma Pipeline
Relapsing refractory multiple myeloma (RRMM) continues to escalate globally, contributing to comorbidities like cardiovascular disease, diabetes, and secondary cancers. According to DelveInsight, over 55 pharmaceutical and biotech companies are developing more than 60 innovative therapeutic candidates spanning clinical and preclinical stages-highlighting a robust pipeline aimed at addressing this critical healthcare challenge.
Explore the Cutting-Edge Landscape of Relapsing refractory multiple myeloma Drug Development @ https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
What Key Developments Does the RRMM Pipeline Report Reveal?
• Over 55 companies are developing more than 60 therapies targeted at RRMM.
In April 2024, the FDA approved the use of Abecma earlier in the treatment sequence for RRMM patients, allowing its use after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
• On August 9, 2023, the FDA approved talquetamab for adults with RRMM who have received at least four prior lines of therapy.
• Key Relapsing refractory multiple myeloma companies such as Bristol-Myers Squibb, I-MAB Biopharma, Pfizer, Arcellx, Gilead sciences, Novartis, Array Biopharma, Hrain Biotechnology Co., Ltd., Cartesian Therapeutics, Xencor, Takeda, Sorrento Therapeutics, Heidelberg Pharma AG, Ichnos Sciences, Allogene Therapeutics, Harpoon Therapeutics, Cellectis, Poseida Therapeutics, Regeneron Pharmaceuticals, ONK Theraputics, TeneoOne, iTeos Therapeutics, Oricell Therapeutics, Anaveon AG, Luminary Therapeutics, Seagen Inc., Trillium Therapeutics Inc., Virtuoso BINco, Inc., Seagen Inc., Trillium Therapeutics Inc., and others are evaluating new drugs for Relapsing refractory multiple myeloma to improve the treatment landscape.
• Promising Relapsing refractory multiple myeloma pipeline therapies in various stages of development include Mezigdomide, Iopofosine, ORIC-533, and others.
Who are the major players driving innovation in RRMM?
Key companies include Bristol Myers Squibb, Pfizer, Novartis, Gilead Sciences, Takeda, Regeneron, Seagen, I-MAB Biopharma, and many others.
Which therapies are gaining the most attention?
Prominent candidates include Mezigdomide, Iopofosine, and ORIC-533, among other promising pipeline therapies.
How Does DelveInsight Define RRMM and Its Clinical Challenges?
Multiple myeloma (MM) is marked by uncontrolled plasma cell growth in bone marrow, sometimes beyond. RRMM refers to disease that returns or resists treatment-often due to genetic mutations enabling drug resistance and immune evasion.
MM often arises from MGUS (monoclonal gammopathy of undetermined significance), a benign precursor present in over 3% of individuals above age 50, with a 1% annual progression risk.
Download the Relapsing refractory multiple myeloma sample report to know in detail about the Relapsing refractory multiple myeloma treatment market @ https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
What are the primary symptoms and diagnostic protocols?
• Symptoms: bone pain, fatigue, infections, renal issues, and less common complications like spinal cord compression.
• Diagnosis: guided by NCCN standards-incorporating blood tests, protein studies, and light chain assays.
How have treatment advances impacted RRMM care?
Novel agents like thalidomide, lenalidomide, and bortezomib, combined with steroids, have paved the way for newer drugs like pomalidomide and carfilzomib.
What Detailed Insights Does the 2025 RRMM Pipeline Report Offer?
• Breakdown of companies developing therapies, and categorization by development stage.
• In-depth analysis of mechanism of action, administration route, molecular type, and combination strategies.
• Strategic overview of collaborations, licensing, and funding trends shaping the RRMM market.
Unlock key insights into emerging Relapsing refractory multiple myeloma therapies and market strategies here: https://www.delveinsight.com/report-store/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Which Emerging Therapies Stand Out?
• Mezigdomide (Bristol Myers Squibb)
A next-generation CELMoD (Cereblon E3 ligase modulator) designed to improve on current immunomodulatory drugs with enhanced efficacy and oral dosing.
• Iopofosine (Cellectar Biosciences)
A targeted Phospholipid Drug ConjugateTM delivering iodine-131 directly to myeloma cells, minimizing healthy tissue exposure. Currently in Phase 2b studies for RRMM and other malignancies.
How Is the RRMM Therapies Pipeline Evaluated?
Relapsing refractory multiple myeloma Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Relapsing refractory multiple myeloma By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Relapsing refractory multiple myeloma Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Relapsing refractory multiple myeloma Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Relapsing refractory multiple myeloma therapies and key Relapsing refractory multiple myeloma companies: https://www.delveinsight.com/sample-request/relapsing-refractory-multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
What Does the RRMM Report Cover?
• What's the market and unmet need?
• What's the current treatment landscape?
• Who are the key players and emerging drugs?
• What clinical trials are in place (Phase I-III)?
• What competitive partnerships and deals are shaping the sector?
• What are the future opportunities and market forecasts?
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsing refractory multiple myeloma Pipeline Outlook 2025 - Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight here
News-ID: 4153021 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Relapsing
Relapsing Refractory Multiple Myeloma Market is expected to reach USD 25 billion …
Relapsing refractory multiple myeloma (RRMM) is a severe form of blood cancer in which the disease recurs despite treatment or becomes resistant to therapy. As one of the most aggressive hematologic cancers, RRMM is characterized by the uncontrolled proliferation of plasma cells in the bone marrow, leading to bone damage, anemia, and kidney dysfunction. While treatments such as chemotherapy, proteasome inhibitors, and immunomodulatory drugs (IMiDs) have been used, RRMM remains…
Relapsing Multiple Sclerosis Market Trends, Therapeutic Advances, and Growth Opp …
Relapsing Multiple Sclerosis (RMS) is a chronic, immune-mediated neurological condition characterized by episodes of acute neurological symptoms followed by periods of remission. Affecting millions globally, RMS imposes significant challenges on patients' quality of life, healthcare systems, and society at large. The Relapsing Multiple Sclerosis Market has gained substantial momentum as pharmaceutical companies, biotechnology firms, and healthcare providers focus on developing innovative disease-modifying therapies (DMTs) and personalized treatment strategies. With advancements…
Relapsing Remitting Multiple Sclerosis Pipeline, Clinical Trials Assessment, and …
DelveInsight's, "Relapsing Remitting Multiple Sclerosis Pipeline Insight 2023" report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in the Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing Remitting Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Global Relapsing-Remitting Multiple Sclerosis Market Research Report 2023-2029
Global Relapsing-Remitting Multiple Sclerosis Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the future. The information presented is based on historical milestones and current…
Relapsing Refractory Multiple Myeloma Market Size in 7MM is expected to change f …
DelveInsight's "Relapsing Refractory Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Relapsing Refractory Multiple Myeloma, historical and forecasted epidemiology as well as the Relapsing Refractory Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover more about therapies set to grab major Relapsing Refractory Multiple Myeloma Market Share @ Relapsing Refractory Multiple Myeloma Market Size-…
Relapsing-Remitting Multiple Sclerosis market: Drivers, Threats, and Opportuniti …
"
The Relapsing-Remitting Multiple Sclerosis global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms of value and volume using the latest research tools and techniques. The report also includes estimates for market share, revenue, production, consumption, gross profit margin, CAGR, and other key…
